BIO3 Share Price

Open 23.10 Change Price %
High 23.10 1 Day -0.08 -0.35
Low 22.90 1 Week -0.24 -1.03
Close 23.00 1 Month 0.00 0.00
Volume 8193 1 Year 10.12 78.57
52 Week High 23.88
52 Week Low 12.02
BIO3 Important Levels
Resistance 2 23.19
Resistance 1 23.11
Pivot 23.00
Support 1 22.89
Support 2 22.81
ETR Germany Most Active Stocks
CBK 11.21 3.41%
CBK 11.21 3.41%
DBK 13.94 2.73%
DBK 13.94 2.73%
EOAN 9.20 -2.75%
EOAN 9.20 -2.75%
DTE 15.34 -2.17%
DTE 15.34 -2.17%
DTE 15.34 -2.17%
DTE 15.34 -2.17%
More..
ETR Germany Top Gainers Stocks
ANO 0.09 80.00%
ANO 0.09 80.00%
ANO 0.09 80.00%
S9H 0.16 45.45%
DUL 93.30 39.61%
DUL 93.30 39.61%
5M71 39.00 13.70%
VSC 5.00 12.36%
VSC 5.00 12.36%
ZSB 0.10 11.11%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
CTAA 6.62 -10.05%
TPE 4.75 -10.04%
R3Q 0.10 -9.09%
IS7 8.61 -7.22%
ITN 0.26 -7.14%
More..

Biotest AG (ETR: BIO3)

BIO3 Technical Analysis 4
As on 21st Sep 2017 BIO3 Share Price closed @ 23.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 18.50 & Buy for SHORT-TERM with Stoploss of 22.75 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO3 Target for September
1st Target up-side 24.06
2nd Target up-side 24.59
3rd Target up-side 25.12
1st Target down-side 22.54
2nd Target down-side 22.01
3rd Target down-side 21.48
BIO3 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO3 Address
BIO3
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO3 Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO3 ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO3 Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.